Diagnostic Use of the Combination of CA72 ‐4 and Tumor Volume in Mucinous Ovarian Tumors
Journal of Obstetrics and Gynaecology Research · 2026
DOI: 10.1111/jog.70177 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2026. Verfasst von Hajime Araki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya-shi, Aichi, Japan. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Tumor Burden, Adenocarcinoma, Mucinous, Antigens, Tumor-Associated, Carbohydrate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Tokai Pathways to Global Excellence, Fusion Oriented REsearch for disruptive Science and Technology, Japan Science and Technology Agency.
Abstract (Originalsprache)
Objective
Mucinous ovarian cancer (MOC) is a rare epithelial ovarian cancer subtype with poor prognosis, particularly in advanced stages. Differentiating MOC from mucinous borderline ovarian tumor (MBT) remains clinically challenging, often leading to delayed or inadequate treatment. Accurate preoperative diagnosis is crucial for guiding surgical strategies and improving patient outcomes. This study evaluated preoperative clinical factors that can distinguish MOC from MBT.
Methods
We retrospectively analyzed 46 ovarian mucinous tumors diagnosed between 2017 and 2021, including 15 MOC and 31 MBT cases confirmed by histopathology. Patient age, tumor laterality, tumor size, tumor markers (CA125, CA19‐9, CA72‐4, CEA), and tumor volume were assessed. Tumor size was measured as the maximum magnetic resonance imaging diameter, whereas volume was calculated using three‐dimensional imaging. Statistical analyses included the Mann–Whitney U test and receiver operating characteristic curve analysis, with AUC as a measure of diagnostic accuracy.
Results
Among the tumor markers, CA72‐4 exhibited the highest diagnostic accuracy (area under the curve [AUC]: 0.834), with significantly higher levels in MOC than in MBT ( p < 0.001). Tumor size alone was an unreliable discriminator (AUC: 0.42). The tumor volume tended to be larger in MBT than in MOC (median: 2 362 878 cm 3 vs. 1 262 436 cm 3 ; p = 0.77). However, the combination of CA72‐4 and tumor volume improved the diagnostic performance (AUC: 0.875).
Conclusion
The combination of CA72‐4 levels and tumor volume enhances preoperative differentiation between MOC and MBT. This combined approach may optimize surgical planning and improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya-shi, Aichi, Japan.
- Nagoya University Institute for Advanced Research, Nagoya, Japan.
- Japan Science and Technology Agency (JST), Saitama, Japan.
ORCID-Profile: Akira Yokoi
Förderung
- Tokai Pathways to Global Excellence
- Fusion Oriented REsearch for disruptive Science and Technology
- Japan Science and Technology Agency
Zitieren
APA
Araki, H., Yokoi, A., Kuroda, K., Suzuki, K., Yoshida, K., Yoshihara, M., Tamauchi, S., Yoshikawa, N., Niimi, K., & Kajiyama, H. (2026). Diagnostic Use of the Combination of CA72 ‐4 and Tumor Volume in Mucinous Ovarian Tumors. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.70177
Vancouver
Araki H, Yokoi A, Kuroda K, Suzuki K, Yoshida K, Yoshihara M, et al. Diagnostic Use of the Combination of CA72 ‐4 and Tumor Volume in Mucinous Ovarian Tumors. Journal of Obstetrics and Gynaecology Research. 2026. doi:10.1111/jog.70177
BibTeX
@article{Araki2026,
author = {Araki, Hajime and Yokoi, Akira and Kuroda, Keita and Suzuki, Kazuhiro and Yoshida, Kosuke and Yoshihara, Masato and Tamauchi, Satoshi and Yoshikawa, Nobuhisa and Niimi, Kaoru and Kajiyama, Hiroaki},
title = {Diagnostic Use of the Combination of CA72 ‐4 and Tumor Volume in Mucinous Ovarian Tumors},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2026},
doi = {10.1111/jog.70177}
}
EUVIMED